mRNA technology has broad application potential, and different disease scenarios pose distinct engineering challenges.
Our focus areas are not just application categories — they represent a systematic practice of how mRNA platform capabilities are designed, validated, scaled up, and delivered. Through continuous iteration across different disease scenarios, we advance mRNA technology from platform innovation toward translatable, manufacturable, and accessible product value.
Preventive Vaccines
Establish a GMP-compliant high-throughput production system that ensures immunogenicity while achieving rapid response, scalable manufacturing, and batch-to-batch consistency.
Tumor Immunology
Enhance antigen design and delivery efficiency to build a rational therapeutic window between efficacy and safety, activate specific immune responses, and support tumor microenvironment remodeling.
Protein Replacement Therapy
Support repeat dosing and long-term expression through sequence optimization and low-immunogenicity design, continuously improving the stability and safety of in vivo protein expression.
Preventive Vaccines
For human and veterinary infectious disease prevention and control, mRNA vaccine development focuses not only on immune protection efficacy but also on the systemic balance among safety, reactogenicity, stability, and scalable production. We continuously optimize antigen design, delivery systems, process scale-up, and quality control to improve immune consistency, batch stability, supply reliability, and regulatory acceptability in large-scale applications, advancing mRNA vaccines from R&D validation toward real-world long-term use. In veterinary and livestock vaccine scenarios, the platform further focuses on per-dose cost control, production efficiency, cold-chain compatibility, and supply chain assurance to meet the higher demands of accessibility and commercial viability in large-scale farming, accelerating the transformation of mRNA technology into sustainable, scalable industrial value.
Tumor Immunology
For therapeutic immunotherapy scenarios, the core challenge of mRNA technology is not merely enhancing immune effects, but achieving directional activation, controllable intensity, and a predictable therapeutic window for immune responses. We systematically optimize mRNA expression kinetics, delivery targeting, and safety thresholds to improve antigen presentation efficiency and specific immune response levels, building a better therapeutic window between efficacy and safety. Through coordinated design of immune activation pathways, delivery systems, and dosing strategies, the platform supports continued expansion into personalized cancer vaccines, tumor-associated antigen vaccines, and combination immunotherapy approaches.
Personalized Cancer Vaccines
The core challenge of personalized cancer vaccines lies in an extremely short production cycle and CMC stability and cost control under a "small-batch, high-frequency" model. The platform must not only rapidly complete the full closed loop from neoantigen screening to GMP production, but also maintain product quality consistency and reproducibility under significant individual variation. The key to the industry lies in breaking through the engineering bottleneck of "personalization makes scaling difficult" through standardization, automation, and modular production.
In Vivo Cell Therapy
The core challenge of in vivo cell therapy lies in precisely balancing efficacy and safety. mRNA expression intensity, duration, and cell specificity must be tightly controlled to reduce off-target effects and immunotoxicity risk. Meanwhile, compared to conventional LNP systems, antibody or ligand-conjugated targeted delivery strategies impose higher requirements on CMC consistency, conjugation efficiency characterization, and process scale-up capability. The key competitive differentiator has shifted from "whether delivery is possible" to "whether delivery can be stable, precise, and industrially viable."
Immune Factors / Immune Modulators
Immune factor products generally have a steep dose-toxicity curve, where minor variations in expression levels can significantly impact efficacy and safety. Therefore, the engineering core is not maximizing expression, but achieving predictable, adjustable, and reproducible immune modulation effects. This requires the platform to build systematic capabilities in mRNA design, delivery efficiency, and in vivo expression regulation to achieve more stable and safer immune modulation output.
Protein Replacement Therapy
Protein replacement and regeneration products are typically intended for long-term, high-frequency chronic dosing scenarios. This imposes higher requirements on delivery system biodistribution, in vivo metabolic kinetics, and immunogenicity control following repeat administration — particularly the need to mitigate the impact of anti-drug antibodies on efficacy and safety. At the same time, compared to short-cycle therapeutic products, these therapies face more complex compliance requirements in clinical follow-up, quality systems, and regulatory approval. The key to industry development lies in balancing technical platform maturity with clinical translatability, achieving long-term, safe, and sustainable therapeutic output through stepwise engineering validation.
